CN113512236A - 一种氧化刺槐豆胶-卡拉胶微球及其制备方法 - Google Patents
一种氧化刺槐豆胶-卡拉胶微球及其制备方法 Download PDFInfo
- Publication number
- CN113512236A CN113512236A CN202110562572.9A CN202110562572A CN113512236A CN 113512236 A CN113512236 A CN 113512236A CN 202110562572 A CN202110562572 A CN 202110562572A CN 113512236 A CN113512236 A CN 113512236A
- Authority
- CN
- China
- Prior art keywords
- locust bean
- bean gum
- carrageenan
- oxidized
- microspheres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
- C08J3/246—Intercrosslinking of at least two polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
- C08B37/0093—Locust bean gum, i.e. carob bean gum, with (beta-1,4)-D-mannose units in the main chain branched with D-galactose units in (alpha-1,6), e.g. from the seeds of carob tree or Ceratonia siliqua; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/07—Aldehydes; Ketones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种氧化刺槐豆胶‑卡拉胶微球及其制备方法,该氧化刺槐豆胶是由天然刺槐豆胶(LBG)与TEMPO/NaBr/NaClO催化氧化体系合成,碱性条件下TEMPO试剂由中间价态的自由基氧化变成最高价态的亚硝基鎓离子,选择性氧化半乳甘露糖链上C‑6位伯羟基,得到的氧化刺槐豆胶与卡拉胶以戊二醛进行交联,于氯化钾溶液中进行固化得到微球;得到的微球可作为载药介质,应用在日化、医药相关领域,其生物相容性好,在胃酸条件下对药物具有缓释释效果,并具有良好的生物降解性。
Description
技术领域
本发明属于高分子材料领域,具体涉及一种氧化刺槐豆胶-卡拉胶微球及其制备方法。
技术背景
刺槐豆胶(LBG)是一种天然的中性半乳甘露聚糖,分子量约30万道尔顿,其结构主要以D-甘露聚糖在1,6位上以β-(1,4)糖苷键连接α-D-吡喃半乳糖,其中半乳糖和甘露糖比例为1:4,是甘露糖含量较多的天然植物籽多糖。据报道,它具有生物相容性、生物吸附性、生物可降解性、非致畸性和非致突变性,表现为粘液粘附行为,其降解产物很容易被排出体外,除了用作增稠剂、稳定剂、乳化剂和胶凝剂之外,也可用于药物制剂和生物医学应用上的赋形剂。
目前报道,天然刺槐豆胶生物相容性好,可生物降解,具有耐酸性,较瓜尔胶更好,因此可作为一种潜在的缓释胃溶或肠溶靶向药物输送系统;但由于其黏度高,部分水不溶,导致其利用度不高,因此对其进行改性同时可提高药物负载率,作为一种潜在的药物缓释运输载体。
发明内容
为了解决上述的技术问题,本发明提供了一种氧化刺槐豆胶-卡拉胶微球的结构和制备方法,本发明的另一个目的在于提供的微球可作为胃溶型载药介质;
所述的氧化刺槐豆胶-卡拉胶微球的结构式如(I)所示:
所述的一种氧化刺槐豆胶-卡拉胶微球的制备步骤为:
1)取2~10g天然刺槐豆胶在80℃下水合2~6h,转移到反应器中,磁力搅拌下,将反应温度升到45~60℃,加入0.1~1g TEMPO试剂和0.5~5gNaBr搅拌均匀后,将pH为9(2MHCl调节)35mL 10~25%(w/v)的NaClO于恒压滴液漏斗中,缓慢滴加,用0.1M等当量的NaOH维持pH为9,滴加完成后继续反应4~7h,加入0.05~0.2g硼氢化钠搅拌30min停止反应,将pH调至8,加入含有NaCl的1~2%反应液体积的乙醇终止反应,布氏漏斗过滤,去离子水多次洗涤至中性,用无水乙醇洗涤3次,将固体物质置于50℃下真空干燥,得到固体氧化刺槐豆胶,4~10℃存储;
其反应流程如(II)所示:
2)将5g混合比例为1:4的氧化刺槐豆胶和卡拉胶粉末加入至90~150mL蒸馏水中搅拌,磁力搅拌逐渐加热升温至50℃,分散均匀后继续升温至80~90℃,并保温0.5~1h,采用真空脱气装置进行高温脱气,除泡0.5~1h,并降温至50~60℃;将模型药物双氯芬酸钠分散于胶液中形成浓度为25%(w/v)的混合溶液,分散均匀后,加入1~5%(w/v)的戊二醛,反应1~2h得胶粘液,静置24h,得到待用胶液;
3)将胶液从21-Ga.针头挤入含0.05%~0.1%(w/v)吐温80的90~150mL的氯化钾溶液中(0.1~0.5%(w/v)),将得到的液滴温育10~60min,并通过过滤收集微水凝胶颗粒(I),用两次蒸馏水洗涤过量的表面盐或离子,风干。
所述步骤(1)中天然刺槐豆胶与催化氧化体系的添加比为1:0.675~1.12;
优选地,天然刺槐豆胶与催化氧化体系的添加比为1:0.995;
优选地,所述步骤中所述制备步骤(1)中氧化时间为6h;
优选地,所述步骤中所述制备步骤(2)混合溶液中戊二醛浓度为4%(w/v);
与现有技术相比,本发明具有如下有益效果:
(1)本发明的氧化刺槐豆胶其羧基含量达3200meq/100g,分子量下降,水溶性和生物相容性好;
(2)本发明的氧化刺槐豆胶-卡拉胶在戊二醛交联剂下,载药率达68.5%,药物释放时间为28~40min左右。
附图说明
图1氧化刺槐豆胶-卡拉胶微球的结构示意图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明了,下面结合具体实施方式,对本发明进一步详细说明。应该理解,这些描述只是示例性的,而并非要限制本发明的范围。此外,在以下说明中,省略了对公知结构和技术的描述,以避免不必要地混淆本发明的概念。
实施例1氧化刺槐豆胶的制备
取8g LBG在80℃下水合6h,转移到反应器中,磁力搅拌下,将反应温度升到50℃,加入0.16g TEMPO试剂和0.8gNaBr搅拌均匀后,将pH为9(2M HCl调节)的35mL 10~25%(w/v)的NaClO于恒压滴液漏斗中,缓慢滴加,用0.1M等当量的NaOH维持pH为9,滴加完成后继续反应6h,加入0.1g硼氢化钠搅拌30min停止反应,将pH调至8,加入含有NaCl的2%反应液体积的乙醇终止反应,布氏漏斗过滤,去离子水多次洗涤至中性,用无水乙醇洗涤3次,将固体物质置于50℃下真空干燥,得到氧化刺槐豆胶,4~10℃存储;
其中LBG与催化氧化体系的具体添加量见表1;
表1:LBG与TEMPO、NaBr、NaClO的添加量
对上述五组样品进行羧基含量、产物得率、数均分子量(Mn)、均重分子量(Mw)、多分散指数(PdI),回转半径(Rg)进行测定,其测定条件如下:
1)羧基含量:按照TAPPI T237 cm-98(2006)标准测定氧化纤维素中多糖羧基含量。本发明取适量氧化刺槐豆胶,以0.1mol/L盐酸溶液处理2h,随后用去离子水洗涤至滤液呈中性,准确量取定量溶液置于锥形瓶中,迅速向锥形瓶中加入50mL事先配好的NaHCO3-NaCl溶液,反应1h后抽滤,取25mL滤液,向其中加入1~2滴甲基红指示剂,随后使用0.01mol/L的盐酸溶液进行滴定。以公式(1)计算羧基含量:
(meq/100g)={B-[A+(A×C/50)]}×N×(200/W) (1)
其中,A为滴定25mL滤液时盐酸溶液的用量,mL;B为滴定NaHCO3-NaCl
溶液时盐酸溶液的用量,m L;C为溶液中水的质量,g;N为滴定所用盐酸溶液的实际浓度mol/L;W为样品绝干质量,g;
2)氧化刺槐豆胶产物得率:通过过滤收集步骤(1)的水不溶部分,并进行充分洗涤除去杂质,小心转移至密封袋中并称重,取样进行水分测试,氧化产物得率按照公式(2)计算:
Y(%)=(W2-W1)×100% (2)
其中,W1为氧化前原料的绝干质量,g;W2为氧化纤维素水不溶部分的绝干质量,g;
3)数均分子量(Mn)、均重分子量(Mw)、多分散指数(PdI),回转半径(Rg):采用三重检测凝胶渗透色谱法(GPC/SEC3),在一个模块化系统进行,该系统包括脱气器、HPLC泵(K-1001)和RI检测器(K-2300)、粘度计(Trisec 270型双检测器)和RALLS组成以及两根PL-aquagel-OH凝胶色谱柱(8μm、300×7.5mm);纯化过程中洗脱液为0.2MNaNO3,0.01MNaH2PO4,0.1%w/v NaN3,pH=7,流速为1mL/min;
按上述测定方法得到的结果见表2;
表2:氧化刺槐豆胶的测定结果
LBG与催化氧化体系的添加比如表1结果可知,在氧化过程中,天然刺槐豆胶与催化氧化体系的添加比为1:0.675~1.12,随着催化氧化体系的添加量增加,LBG的氧化程度增加,羧基含量由2.0k增加至3.2k,分子量较空白LBG明显下降,表明氧化过程中,大分子链会解聚,因此分散度和回转半径同时下降,直到LBG与催化氧化体系比为1:0.995(1-4)反应最充分。
实施例2氧化刺槐豆胶的制备
取8g LBG在80℃下水合6h,转移到反应器中,磁力搅拌下,将反应温度升到50℃,加入0.16g TEMPO试剂和0.8g NaBr搅拌均匀后,将pH为9(2M HCl调节)的35mL 20%(w/v)的NaClO于恒压滴液漏斗中,缓慢滴加,用0.1M等当量的NaOH维持pH为9,滴加完成后继续反应4、5、6、7h(记为2-1、2-2、2-3、2-4),加入0.1g硼氢化钠搅拌30min停止反应,将pH调至8,加入含有NaCl的2%反应液体积的乙醇终止反应,布氏漏斗过滤,去离子水多次洗涤至中性,用无水乙醇洗涤3次,将固体物质置于50℃下真空干燥,得到氧化刺槐豆胶,4~10℃存储;
对上述五组样品进行羧基含量、产物得率、数均分子量(Mn)、均重分子量(Mw)、多分散指数(PdI),回转半径(Rg)进行测定,其测定条件同实施例1,得到的结果见表3;
表3:氧化刺槐豆胶的测定结果
上述五组样品的氧化结果由表2可见,随着氧化时间的增加,羧基含量由1.8k增加至3.2k,分子量较空白LBG明显下降,表明氧化过程中,大分子链会解聚,因此分散度和回转半径同时下降,直到氧化时间为6h反应最充分,继续增加氧化时间,氧化程度不再发生明显变化。
实施例3微球的制备
将5g混合比例为1:4的氧化刺槐豆胶和卡拉胶粉末加入至100mL蒸馏水中搅拌,磁力搅拌逐渐加热升温至50℃,分散均匀后继续升温至80~90℃,并保温0.5~1h,采用真空脱气装置进行高温脱气,除泡0.5~1h,并降温至50~60℃;将模型药物双氯芬酸钠分散于胶液中形成浓度为25%(w/v)的混合溶液,分散均匀后,分别加入戊二醛形成浓度为的1、2、3、4、5%(w/v)混合溶液(记为3-1、3-2、3-3、3-4、3-5),反应2h得胶粘液,静置24h,将该胶液从21-Ga.针头挤入含0.05%(w/v)吐温80的100mL的氯化钾溶液中0.2%(w/v),将液滴温育45min,并通过过滤收集微水凝胶颗粒(I),用两次蒸馏水洗涤过量的表面盐或离子,风干;
对上述五组样品进行药物负载率以及完全释放时间考察,其测定条件如下:
1)药物负载率:将10mg微球颗粒粉碎,放入100mL的模拟胃液中过夜,使负载药物完全溶解,悬浮液过滤,滤液在276nm处用紫外分光光度计分析,根据式(3)计算药物负载率,取三次平均值:
2)完全释放时间:测试微水凝胶在模拟胃液中的即刻释放行为,将50mg样品放入500mL 0.1N的HCl溶液(pH=1.5)中,(50rpm、37±0.5℃),记录粒子完全崩解所需的时间,取三次平均值。
按上述测定方法得到的测定结果见表4;
表4:氧化刺槐豆胶-卡拉胶微球的测定结果
戊二醛的添加使得氧化刺槐豆胶与卡拉胶的交联情况可由表3中微球的负载率反映,实施例3中戊二醛的添加量为1~5%,随着戊二醛含量增加,药物负载率由38.5%增加至68.5%,且药物在模拟胃液中的释放时间由28min增加至40min,表明戊二醛使得体系的交联程度增加,药物负载量大且牢固,在酸性模拟胃液中微球崩解的速率下降,可作为胃溶型缓释药物载体。
Claims (7)
2.根据权利要求1所述的一种氧化刺槐豆胶-卡拉胶微球,其特征在于:所述的氧化刺槐豆胶-卡拉胶微球可作为胃溶型载药介质。
3.一种氧化刺槐豆胶-卡拉胶微球的制备方法,其特征在于,所述微球制备步骤为:
1)取2~10g天然刺槐豆胶在80℃下水合2~6h,转移到反应器中,磁力搅拌下,将反应温度升到45~60℃,加入0.1~1g TEMPO试剂和0.5~5gNaBr搅拌均匀后,将pH为9(2M HCl调节)35mL 10~25%(w/v)的NaClO于恒压滴液漏斗中,缓慢滴加,用0.1M等当量的NaOH维持pH为9,滴加完成后继续反应4~7h,加入0.05~0.2g硼氢化钠搅拌30min停止反应,将pH调至8,加入含有NaCl的1~2%反应液体积的乙醇终止反应,布氏漏斗过滤,去离子水多次洗涤至中性,用无水乙醇洗涤3次,将固体物质置于50℃下真空干燥,得到固体氧化刺槐豆胶,4~10℃存储;
2)将5g混合比例为1:4的氧化刺槐豆胶和卡拉胶粉末加入至90~150mL蒸馏水中搅拌,磁力搅拌逐渐加热升温至50℃,分散均匀后继续升温至80~90℃,并保温0.5~1h,采用真空脱气装置进行高温脱气,除泡0.5~1h,并降温至50~60℃;将模型药物双氯芬酸钠分散于胶液中形成浓度为25%(w/v)的混合溶液,分散均匀后,加入1~5%(w/v)的戊二醛,反应1~2h得胶粘液,静置24h,得到待用胶液;
3)将待用胶液从21-Ga.针头挤入含0.05%~0.1%(w/v)吐温80的90~150mL的氯化钾溶液中,将得到的液滴温育10~60min,并通过过滤收集微水凝胶颗粒(I),用两次蒸馏水洗涤过量的表面盐或离子,风干。
4.根据权利要求3所述的一种氧化刺槐豆胶-卡拉胶微球的制备方法,其特征在于:所述步骤(1)中天然刺槐豆胶与催化氧化体系的添加比为1:0.675~1.12。
5.根据权利要求3或4所述的一种氧化刺槐豆胶-卡拉胶微球的制备方法,其特征在于:所述步骤(1)中天然刺槐豆胶与催化氧化体系的添加比为1:0.995。
6.根据权利要求3所述的一种氧化刺槐豆胶-卡拉胶微球的制备方法,其特征在于:所述步骤中所述制备步骤(1)中氧化时间为6h。
7.根据权利要求3所述的一种氧化刺槐豆胶-卡拉胶微球的制备方法,其特征在于:所述步骤中所述制备步骤(2)混合溶液中戊二醛浓度为4%(w/v)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110562572.9A CN113512236A (zh) | 2021-05-24 | 2021-05-24 | 一种氧化刺槐豆胶-卡拉胶微球及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110562572.9A CN113512236A (zh) | 2021-05-24 | 2021-05-24 | 一种氧化刺槐豆胶-卡拉胶微球及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113512236A true CN113512236A (zh) | 2021-10-19 |
Family
ID=78064883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110562572.9A Withdrawn CN113512236A (zh) | 2021-05-24 | 2021-05-24 | 一种氧化刺槐豆胶-卡拉胶微球及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113512236A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015087083A1 (en) * | 2013-12-13 | 2015-06-18 | Cipla Limited | Intranasal pharmaceutical compositions of polymeric nanoparticles |
CN112300449A (zh) * | 2020-11-03 | 2021-02-02 | 赵书敏 | 一种改性刺槐豆胶-kappa型卡拉胶凝胶及其制备方法 |
CN112314935A (zh) * | 2020-11-19 | 2021-02-05 | 华中农业大学 | 一种胶原蛋白-多糖复合水凝胶制备方法及其产品 |
-
2021
- 2021-05-24 CN CN202110562572.9A patent/CN113512236A/zh not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015087083A1 (en) * | 2013-12-13 | 2015-06-18 | Cipla Limited | Intranasal pharmaceutical compositions of polymeric nanoparticles |
CN112300449A (zh) * | 2020-11-03 | 2021-02-02 | 赵书敏 | 一种改性刺槐豆胶-kappa型卡拉胶凝胶及其制备方法 |
CN112314935A (zh) * | 2020-11-19 | 2021-02-05 | 华中农业大学 | 一种胶原蛋白-多糖复合水凝胶制备方法及其产品 |
Non-Patent Citations (4)
Title |
---|
CAROLINE NOVAK SAKAKIBARA等: "TEMPO-mediated oxidation on galactomannan: Gal/Man ratio and chain flexibility dependence", 《CARBOHYDRATE POLYMERS》 * |
PASCAL AUDET等: "Immobilized growing lactic acid bacteria with x-carrageenan — locust bean gum gel", 《APPL MICROBIOL BIOTECHNOL》 * |
SABYASACHI MAITI等: "Novel gastroulcer protective micro(hydro)gels of sulfated locust bean gum-aluminium complex for immediate release of diclofenac sodium", 《JOURNAL OF DRUG TARGETING》 * |
郑迪等: "响应面法优化卡拉胶-刺槐豆胶软胶囊胶皮的制备工艺", 《食品工业科技》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
George et al. | Guar gum: Versatile natural polymer for drug delivery applications | |
Nayak et al. | Trigonella foenum-graecum L. seed mucilage-gellan mucoadhesive beads for controlled release of metformin HCl | |
Anwar et al. | Alginate-polyvinyl alcohol based interpenetrating polymer network for prolonged drug therapy, optimization and in-vitro characterization | |
Nayak et al. | Tamarind seed polysaccharide–gellan mucoadhesive beads for controlled release of metformin HCl | |
Nayak et al. | Blends of jackfruit seed starch–pectin in the development of mucoadhesive beads containing metformin HCl | |
Song et al. | Self-assembled micelles based on hydrophobically modified quaternized cellulose for drug delivery | |
Nayak et al. | Development of pectinate-ispagula mucilage mucoadhesive beads of metformin HCl by central composite design | |
Kaloti et al. | Kinetics of coacervation transition versus nanoparticle formation in chitosan–sodium tripolyphosphate solutions | |
CN106543454B (zh) | 一种低溶胀可生物降解医用光聚合型水凝胶及其制备方法 | |
Pan et al. | Novel multi-responsive and sugarcane bagasse cellulose-based nanogels for controllable release of doxorubicin hydrochloride | |
Messaoud et al. | Influence of internal composition on physicochemical properties of alginate aqueous-core capsules | |
Kamoun et al. | Influence of degree of substitution and folic acid coinitiator on pullulan-HEMA hydrogel properties crosslinked under visible-light initiating system | |
Ganie et al. | Preparation, characterization, release and antianemic studies of guar gum functionalized iron complexes | |
Malviya et al. | Synthesis of Aloevera/Acrylonitrile based Nanoparticles for targeted drug delivery of 5-Aminosalicylic acid | |
Cassano et al. | Preparation, characterization and in vitro activities evaluation of curcumin based microspheres for azathioprine oral delivery | |
Işıklan et al. | Development and characterization of dual sensitive poly (N, N-diethyl acrylamide) grafted alginate microparticles | |
Chen et al. | Chemical modification of alginate via the oxidation-reductive amination reaction for the development of alginate derivative electrospun composite nanofibers | |
Nayak et al. | Particulate matrices of ionotropically gelled alginate-and plant-derived starches for sustained drug release | |
CN113512236A (zh) | 一种氧化刺槐豆胶-卡拉胶微球及其制备方法 | |
Raj et al. | Formulation and evaluation of chitosan prazosin beads by ionotropic gelation method | |
CN106581647A (zh) | 一种pH响应胰岛素缓释纳米粒及其制备方法和应用 | |
Panda et al. | Process optimization, Formulation and evaluation of hydrogel {Guargum-G-Poly (Acrylamide)} based Doxofylline microbeads | |
CN114605600B (zh) | 一种酯酶响应的两亲性线性聚合物及其制备方法与应用 | |
CN104906040A (zh) | K+响应型靶向胞内释药的两亲嵌段共聚物载药胶束及其制备方法 | |
CN111410757B (zh) | 一种可降解及环境响应性复合物微凝胶的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20211019 |
|
WW01 | Invention patent application withdrawn after publication |